IDXG - Interpace Diagnostics Group, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7835
+0.0032 (+0.41%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.7803
Open0.7710
Bid0.0000 x 1100
Ask0.0000 x 1800
Day's Range0.7710 - 0.7949
52 Week Range0.6700 - 1.5500
Volume60,568
Avg. Volume156,109
Market Cap29.927M
Beta (3Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.4850
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.02
Trade prices are not sourced from all markets
  • GlobeNewswire

    Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Company’s July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. (CGIX). The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019.

  • Can We See Significant Institutional Ownership On The Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Share Register?
    Simply Wall St.

    Can We See Significant Institutional Ownership On The Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Share Register?

    The big shareholder groups in Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) have power over the company...

  • GlobeNewswire

    Interpace Named to ‘Most Admired Companies’ List

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies whose industry achievements break new technological ground and who’s company cultures and values represent a commitment to innovation. “We are pleased to be recognized by The Silicon Review as one of the 50 Most Admired Companies as we continue to push the envelope in providing diagnostic tests and biopharma services to help assess the risk of cancer progression and select the best treatment for patients”, said Jack Stover, CEO of Interpace.

  • GlobeNewswire

    Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with 3 independent Blue Cross Blue Shield (BCBS) plans totaling nearly 5 million covered lives across Alabama, Arkansas, and Arizona. The ThyGeNEXT® - ThyraMIR® combination represents the first and only test on the market that includes the rule-out properties of next-generation sequencing of a patient’s DNA and RNA along with the rule-in capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.

  • GlobeNewswire

    Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference

    PARSIPPANY, NJ, Sept. 18, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.

  • GlobeNewswire

    Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China

    Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC.

  • GlobeNewswire

    Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright

    PARSIPPANY, NJ, Sept. 06, 2019 -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming.

  • Thomson Reuters StreetEvents

    Edited Transcript of IDXG earnings conference call or presentation 13-Aug-19 12:30pm GMT

    Q2 2019 Interpace Diagnostics Group Inc Earnings Call

  • GlobeNewswire

    Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    MINNEAPOLIS, Aug. 19, 2019 -- Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional.

  • GlobeNewswire

    Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update

    Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased.

  • ACCESSWIRE

    Interpace Diagnostics Group, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...

  • GlobeNewswire

    Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019

    PARSIPPANY, NJ, Aug. 06, 2019 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it will report its second quarter 2019 financial results on Tuesday,.

  • GlobeNewswire

    Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has contracted with Blue Cross Blue Shield (BCBS) of Michigan, a not-for-profit independent member of the Blue Cross Blue Shield Association with 4.5 million members in the State of Michigan, making it the largest payer in the State, along with another 1.6 million members across multiple other States. The contract makes the ThyGeNEXT® and ThyraMIR® tests both covered services as well as in-network services for their total of 6 million members.

  • GlobeNewswire

    Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR®

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has entered in to a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests in-network services for their 4 million lives.  Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2018 and now members will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses and optimize their benefits in accordance with their in-network benefit levels. According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades.

  • GlobeNewswire

    Interpace Announces New Agreement with SelectHealth

    Interpace Diagnostics Group, Inc. (IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its proprietary thyroid cancer assays, ThyGeNEXT® and ThyraMIR® to SelectHealth’s more than 850,000 members in Utah and Idaho. Physicians across SelectHealth’s entire network will now be able to utilize Interpace’s thyroid tests to assess indeterminate thyroid nodules thereby providing physicians with additional diagnostic options.

  • Benzinga

    Interpace Diagnostics Partners With AI Specialist To Diagnose Thyroid Cancer

    Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced it completed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), which is focused on applying artificial intelligence to personalized medicine and drug discovery. It's estimated that the treatment market for thyroid cancer was valued at approximately $340 million in 2018 and is expected to reach $2.1 billion by the end of 2025. Under the agreement, the companies will develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations.

  • GlobeNewswire

    Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ:POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery. As part of this agreement, the Companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace’s Thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with Helomics’ patient-derived tumor profiling and AI platform known as “D-CHIP.” Under the plan for this phase of the agreement Helomics will build a model using Interpace’s existing clinical data which can be utilized to identify druggable targets for treatment of indolent and aggressive thyroid cancers.

  • Benzinga

    Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

    Cancer Genetics (NASDAQ: CGIX ) shares are trading sharply higher after Interpace Diagnostics (NASDAQ: IDXG ) said it purchased the Biopharma Services unit of the Cancer Genetics. Interpace Diagnostics ...

  • GlobeNewswire

    Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners

    Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”), announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. In conjunction with this acquisition Ampersand Capital Partners, one of the leading private equity firms in the diagnostic/biopharma sector, agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock, a portion of which will be subject to approval by Interpace’s shareholders.

  • Those Who Purchased Interpace Diagnostics Group (NASDAQ:IDXG) Shares Five Years Ago Have A 98% Loss To Show For It
    Simply Wall St.

    Those Who Purchased Interpace Diagnostics Group (NASDAQ:IDXG) Shares Five Years Ago Have A 98% Loss To Show For It

    Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...

  • GlobeNewswire

    Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross

    Interpace Diagnostics Group, Inc. (IDXG) announced today that its ThyGeNEXT™ and ThyraMIR® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its members who meet established medical criteria for the tests. Interpace’s testing is made available to its members by its strategic partner, LabCorp (LH), Independence’s primary lab services provider, through LabCorp’s Dianon Pathology specialty laboratory.

  • GlobeNewswire

    Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer

    Interpace Diagnostics Group, Inc. (IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the World Congress on Thyroid Cancer, which is being held in Rome, Italy from June 20-22, 2019. The presentation will detail outcomes of a study with patients using Interpace’s ThyGenX® and ThyGeNEXT® in combination with microRNA (miRNA) testing in indeterminate thyroid nodules. “I am excited to present findings from Interpace’s thyroid study at the World Congress on Thyroid Cancer,” stated Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer.

  • Thomson Reuters StreetEvents

    Edited Transcript of IDXG earnings conference call or presentation 13-May-19 8:30pm GMT

    Q1 2019 Interpace Diagnostics Group Inc Earnings Call

  • GlobeNewswire

    Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update

    Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast.

  • GlobeNewswire

    Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

    PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) --  Interpace Diagnostics Group, Inc. (IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® (“DDW”). The meeting will be held in San Diego, CA on May 18-21, 2019, and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.